<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2221-2434</journal-id>
<journal-title><![CDATA[Revista Finlay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Finlay]]></abbrev-journal-title>
<issn>2221-2434</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Cienfuegos. Centro Provincial de información de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2221-24342021000300307</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diagnóstico y tratamiento de los feocromocitomas y paragangliomas]]></article-title>
<article-title xml:lang="en"><![CDATA[Pheochromocytomas and Paragangliomas Diagnosis and Treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soriano Lorenzo]]></surname>
<given-names><![CDATA[Jorge Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Superior de Ciencias Médicas de La Habana Victoria de Girón  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>11</volume>
<numero>3</numero>
<fpage>307</fpage>
<lpage>315</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2221-24342021000300307&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2221-24342021000300307&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2221-24342021000300307&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Los feocromocitomas y los paragangliomas son tumores neuroendocrinos productores de catecolaminas provenientes del sistema nervioso simpático o parasimpático. Se originan en las células cromafines de la medula suprarrenal y los ganglios simpáticos extra-adrenales. Su incidencia anual es de 2-8 casos por un millón de personas. El 70 % son esporádicos y un 30 % están asociados a síndromes genéticos familiares con mutaciones en la línea germinal de genes como: NF1, VHL, RET y SDHx. Los pacientes generalmente presentan la triada clásica de cefaleas, palpitaciones y diaforesis. La hipertensión puede presentarse de forma sostenida o paroxística. El diagnóstico requiere de la confirmación por métodos bioquímicos de elevación de las catecolaminas y metanefrinas fraccionadas en plasma u orina de 24 horas, además de evidencia imagenológica de localización del tumor. El tratamiento de elección es la cirugía, aunque previo a su realización los pacientes deben tener controlada la hipertensión. En los casos de tumores malignos se recomienda el tratamiento con radiaciones y quimioterapia. En la actualidad se estudia el beneficio de muchas terapias dirigidas contra dianas moleculares en estos pacientes. El presente artículo se propone realizar una revisión de los aspectos biológicos de este tumor, su presentación clínica, métodos para el diagnóstico y estrategias terapéuticas más recientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Pheochromocytomas and paragangliomas are catecholamine-producing neuroendocrine tumors from the sympathetic or parasympathetic nervous system. They originate in the chromaffin cells of the adrenal medulla and the extra-adrenal sympathetic ganglia. Its annual incidence is 2-8 cases per one million people. The 70 % are sporadic and the 30 % are associated with familial genetic syndromes with mutations in the germ line of genes such as: NF1, VHL, RET and SDHx. Patients generally suffer from headaches, palpitations, and sweating. Hypertension can present in a sustained or paroxysmal form. Diagnosis requires confirmation by biochemical methods of elevation of fractionated catecholamines and metanephrines in plasma or urine for 24 hours, in addition to imaging evidence of tumor location. The treatment of choice is surgery, although prior to its performance, patients must have hypertension under control. In cases of malignant tumors, treatment with radiation and chemotherapy is recommended. The benefit of many therapies directed against molecular targets in these patients is currently being studied. This article aims to carry out a review of this tumor biological aspect, its clinical presentation, diagnostic methods and the most recent therapeutic strategies.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[feocromocitoma]]></kwd>
<kwd lng="es"><![CDATA[paraganglioma]]></kwd>
<kwd lng="es"><![CDATA[diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[terapéutica]]></kwd>
<kwd lng="en"><![CDATA[pheochromocytoma]]></kwd>
<kwd lng="en"><![CDATA[paraganglioma]]></kwd>
<kwd lng="en"><![CDATA[diagnosis]]></kwd>
<kwd lng="en"><![CDATA[therapeutics]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fishbein]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pheochromocytoma and paraganglioma genetics, diagnosis and treatment]]></article-title>
<source><![CDATA[Hematol Oncol Clin North Am]]></source>
<year>2016</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>135-50</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[WF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Médula suprarrenal, catecolamina y feocromocitoma]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Goldman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schafer]]></surname>
<given-names><![CDATA[AI.]]></given-names>
</name>
</person-group>
<source><![CDATA[Goldman-Cecil Tratado de Medicina Interna]]></source>
<year>2016</year>
<edition>25</edition>
<page-range>380-99</page-range><publisher-loc><![CDATA[. Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[MQ]]></given-names>
</name>
<name>
<surname><![CDATA[Bezerra]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Mendonca]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Latronico]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Fragoso]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary malignant tumors of the adrenal glands.]]></article-title>
<source><![CDATA[Clinics]]></source>
<year>2018</year>
<volume>73</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maligmant pheochromocytoma-paraganglioma pathogenesis, TNM staging, and current clinical trials]]></article-title>
<source><![CDATA[Curr Opin Endocrinol Diabetes Obes]]></source>
<year>2017</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>174-83</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Favier]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Amar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gimenez]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paraganglioma and phaeochromocytoma from genetics to personalized medicine]]></article-title>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2015</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>101-11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fishbein]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Leshchiner]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Walter]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Danilova]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comprehensive molecular characterization of pheochromocytoma and paraganglioma]]></article-title>
<source><![CDATA[Cancer Cell]]></source>
<year>2017</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>181-93</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neumann]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Eng]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pheocromocytoma and paraganglioma]]></article-title>
<source><![CDATA[New Eng J Med]]></source>
<year>2019</year>
<volume>381</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>552-65</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamidi]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Gruber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Smestad]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of patients with metastatic phaeochromocytoma and paraganglioma A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Clin Endocrinol]]></source>
<year>2017</year>
<volume>87</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>440-50</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eisenhofer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Prejbisz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peitzsch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pamporaki]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Masjkur]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rogowski]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biochemical diagnosis of Chromaffin cell tumors in patients at high and low risk of disease Plasma versus urinary free or deconjugated O-methylated catecholamine metabolites]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2018</year>
<volume>64</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1646-56</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyd]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Sadrzadeh]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Pamporaki]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pacak]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Deutschbein]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2019</year>
<volume>181</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>301-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plouin]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Amar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dekkers]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Fassnacht]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gimenez]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Lenders]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2016</year>
<volume>174</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>G1-G10</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fassnacht]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arlt]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Bancos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dralle]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Newell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sahdev]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of adrenal incidentalomas European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2016</year>
<volume>175</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>G1-G34</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naranjo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dodd]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perioperative management of pheochromocytoma]]></article-title>
<source><![CDATA[J Cardiothorac Vasc Anesth]]></source>
<year>2017</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1427-39</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Livingstone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Duttchen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sunderani]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hawboldt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemodynamic stability during pheochromocytoma resection lessons learned over the last two decades]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2015</year>
<volume>22</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>4175-80</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<collab>van der Zee PA.de Boer A</collab>
<article-title xml:lang=""><![CDATA[Pheochromocytoma a review on preoperative treatment with phenoxybenzamine or doxazosin]]></article-title>
<source><![CDATA[Neth J Med]]></source>
<year>2014</year>
<volume>72</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>190-201</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddiqi]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Laird]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Doherty]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of oral nicardipine and magnesium sulfate infusion during preparation and resection of pheochromocytomas]]></article-title>
<source><![CDATA[Surgery]]></source>
<year>2012</year>
<volume>152</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1027-36</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunaud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Boutami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Finnerty]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Germain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weryha]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Both preoperative alpha and calcium channel blockade impact intraoperative hemodynamic stability similarly in the management of pheochromocytoma]]></article-title>
<source><![CDATA[Surgery]]></source>
<year>2014</year>
<volume>156</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1410-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ayala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Waguespack]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Habra]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>2018</year>
<volume>268</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>172-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ball]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Hemal]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Allaf]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International consultation on urological diseases and european association of urology international consultation on minimally invasive surgery in urology laparoscopic and robotic adrenalectomy]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2017</year>
<volume>119</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-21</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toniato]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Boschin]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Opocher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guolo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pellizo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mantero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment]]></article-title>
<source><![CDATA[Surgery]]></source>
<year>2007</year>
<volume>141</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>723-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nölting]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pacak]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastatic phaeochromocytoma spinning towards more promising treatment options]]></article-title>
<source><![CDATA[Exp Clin Endocrinol Diabetes]]></source>
<year>2019</year>
<volume>127</volume>
<numero>2-03</numero>
<issue>2-03</issue>
<page-range>117-28</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Hulsteijn]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Niemeijer]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Dekkers]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clin]]></article-title>
<collab>Corssmit EP I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: Systematic review and meta-analysis</collab>
<source><![CDATA[Endocrinol]]></source>
<year>2014</year>
<volume>80</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>487-501</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sze]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Goddard]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Amendra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shieh]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Plowman]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sequelae and survivorship in patients treated with (131)I-MIBG therapy]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2013</year>
<volume>109</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>565-72</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nastos]]></surname>
<given-names><![CDATA[K,]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[VTF,]]></given-names>
</name>
<name>
<surname><![CDATA[Toumpanakis]]></surname>
<given-names><![CDATA[C,]]></given-names>
</name>
<name>
<surname><![CDATA[Navalkissoor]]></surname>
<given-names><![CDATA[S,]]></given-names>
</name>
<name>
<surname><![CDATA[Quigley]]></surname>
<given-names><![CDATA[AM,]]></given-names>
</name>
<name>
<surname><![CDATA[Caplin]]></surname>
<given-names><![CDATA[M,]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peptide receptor radionuclide treatment and 131I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas]]></article-title>
<source><![CDATA[J Surg Oncol.]]></source>
<year>2017</year>
<volume>115</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>425-34</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ayala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chougnet]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Habra]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Leboulleux]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cabanillas]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2012</year>
<volume>97</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>4040-50</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
